Skip to main content
. 2021 Oct 30;18(21):11452. doi: 10.3390/ijerph182111452
CPI Checkpoint inhibitor
DLT Dose-limiting toxicity
HDAC Histone deacetylase
ICI Immune checkpoint inhibitor
IDO Indoleamine 2,3-dioxygenase
MTD Maximum tolerated dose
NSCLC Non-small cell lung cancer
ODC Optimal dose combination
PARP Poly-ADP-ribose polymerase
PD-1 Programmed death-1
PD-L1 Programmed death ligand-1
VEGF Vascular endothelial growth factor